Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss ...

Facing steep competition, Novo Nordisk has slashed the price for its weight loss drug Wegovy — temporarily, at least.

It's plainly apparent that Novo Nordisk has had May 22 circled its calendar since February, when the FDA began the countdown ...

Among patients who experienced an early cardiovascular event, those treated with semaglutide had approximately 40% fewer ...

with both studies using the same 2.4mg dose of calcitonin receptor agonist cagrilintide and 2.4mg of GLP-1 agonist semaglutide. Novo Nordisk has not yet indicated why it thinks the topline weight ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Novo Nordisk (NVO) (OTCPK:NONOF) on Thursday announced a new initiative to promote its blockbuster weight loss therapy Wegovy ...